ClinicalTrials.gg
CompletedNCT00436839Updated Jul 9, 2012

Taxotere Prostate Cancer New Indication Registration Trial in China

A Phase 3 interventional study of Docetaxel and Mitoxantrone in Prostatic Neoplasms, sponsored by Sanofi. Completed at 1 site in China. Open to male participants. Per ClinicalTrials.gov, last updated 2012-07-09.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
228
Allocation
Randomized
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 193 studies testing docetaxel in Prostatic Neoplasms — 15 open to participants now, 24 under way, 10 of them phase 3. Docetaxel · Prostatic Neoplasms.

Enrollment
30th of 185
228 · median 39
Started
2007
with 19 others
Phase 3
30 of 193
5 open now
Registered
77th of 193
by date
Lead sponsor
11 of 193
Sanofi

Among the 193 studies testing docetaxel in Prostatic Neoplasms, this one is the 30th largest by enrollment of the 185 interventional ones that give a count, is one of 20 that started in 2007, is one of 30 in phase 3, and was the 77th registered.

Prostatic Neoplasms

7,053 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

15 of the 193 studies testing docetaxel in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,233 Prostatic Neoplasms studies recruiting now, 931 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies testing docetaxel in Prostatic Neoplasms, or all of them as a file.
02

Study summary

To compare overall survival after receiving mitoxantrone and prednisone or docetaxel and prednisone in subjects with hormone-refractory metastatic prostate cancer.

03

Conditions studied

  • Prostatic Neoplasms

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically proven prostate adenocarcinoma
  • Androgen independent prostate Cancer S/P orchiectomy and/or LHRH agonist Testosterone \< 50 ng/dl (ie 1.735 nmol/l)
  • Documented progressive disease
  • Patients should have achieved stable analgesia for 7 days
  • Performance Status ≥ 70
  • No prior treatment with cytotoxic agent (except estramustine)
  • Normal cardiac function must be confirmed by
  • Adequate organ function:

    1. Hematology:

      • Neutrophils > 1.5 x 10\^9/L
      • > 10 g/dl. Erythropoietin use is allowed, but red blood cell transfusion to upgrade the hemoglobin level is not allowed
      • > 100 x 10\^9/L
    2. Hepatic function:

      • Total \< the upper-normal limit of the institution.
      • and Aspartate transaminase \< 1.5 times the upper-normal limit of the institution.
    3. Renal function:

      • Creatinine \< 1.5 times the upper normal limit (ie National Cancer Institution grade \< 1)
  • No brain or

Exclusion criteria

Exclusion Criteria:

  • Prior radiotherapy to >25% of bone marrow (whole pelvic irradiation is not allowed)
  • prior cytotoxic chemotherapy, except monotherapy with estramustine
  • prior isotope therapy
  • history of another cancer within the preceding five year
  • symptomatic peripheral neuropathy grade ≥ 2
  • other serious illness or medical condition:

    1. Congestive heart failure even if controlled. Previous history of myocardial infarction or angina pectoris within 1 year from study entry, uncontrolled hypertension or uncontrolled arrhythmias.
    2. Active uncontrolled infection
    3. Peptic ulcer, unstable diabetes mellitus or other for the use of .
    4. Auto-immune disease (lupus, sclerodermia, rheumatoid polyarthritis)
  • treatment with any other anti-cancer therapy
  • treatment with bisphosphonates

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
228 participants (actual)

Study arms

  • Experimental
    1

    Docetaxel 75mg/m² intravenously (day 1) every 21 days, plus prednisone 10mg orally given daily, minimal for 6 cycles and up to 10 cycle

    Drug: Docetaxel · Drug: Prednisone

  • Active comparator
    2

    Mitoxantrone 12mg/m² intravenously every 21 days, plus prednisone 10mg orally given daily, minimal for 6 cycles and up to 10 cycle

    Drug: Mitoxantrone · Drug: Prednisone

Interventions

06

What researchers measure

Primary outcomes

  1. Efficacy: Overall survival

    Time frame: From beginning to end of the study

  2. Objective response rate of patients with measurable disease by Response Evaluation Criteria in Solid tumours

    Time frame: From beginning to end of study

  3. Prostatic Specific Antigen response

    Time frame: From the beginning to the end of study

  4. Pain response (McGill-Melzack Scale)

    Time frame: From beginning to end of study

  5. Time to progression

    Time frame: From beginning to end of study

  6. Adverse event

    Time frame: From beginning to end of study

  7. Quality Of Life: Functional assessment of chronic illness therapy-prostate questionnaire will be used

    Time frame: From beginning to end of study

07

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Shanghai, China
08

References and documents

Publications

  • Zhou T, Zeng SX, Ye DW, Wei Q, Zhang X, Huang YR, Ye ZQ, Yang Y, Zhang W, Tian Y, Zhou FJ, Jie J, Chen SP, Sun Y, Xie LP, Yao X, Na YQ, Sun YH. A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer. PLoS One. 2015 Jan 27;10(1):e0117002. doi: 10.1371/journal.pone.0117002. eCollection 2015. PubMed 25625938 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2007
First posted
Feb 19, 2007
Start
Jan 2007
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Last update
Jul 9, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00436839
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Feb 19, 2007
Start date
Jan 2007
Primary completion
Jun 2012
Completion
Jun 2012
Last update
Jul 9, 2012

Study contacts

Jing Fu
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Docetaxel

Start the discussion